Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2009-02-27
2011-11-01
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S205100, C424S218100, C435S235100, C435S320100
Reexamination Certificate
active
08048427
ABSTRACT:
The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
REFERENCES:
patent: 7524508 (2009-04-01), Pang et al.
patent: 99/28487 (1999-06-01), None
Behrens set al., “Characterization of an Autonomous Subgenomic Pestivirus RNA Replicon”, Journal of Virology, 72 (3), pp. 2364-2372 (1998).
Fields et al., Virology, Third Edition, pp. 931-937 (1996).
Varnavski et al., “Noncytopathic Flavivirus Replicon RNA-Based System for Expression and Delivery of Heterologous Genes”, Virology, vol. 255, pp. 366-375 (1999).
Khromykh et al., “cis- and trans-acting Elements in Flavivirus RNA Replication”, Journal of Virology, 74(7), pp. 3253-3263 (2000).
Proutski et al., “Biological consequences of deletions within the 3′-untraslated region of flaviviruses may be due to rearrangements of RNA secondary structure”, Virus Research 64, pp. 107-123 (1999).
Corver et al., “Fine Mapping of a cis-acting Sequence Element in Yellow Fever Virus RNA that is Required for RNA Replication and Cyclization”, Journal of Virology, 77(3), pp. 2265-2270 (2003).
Khromykh et al., Journal of Virology, vol. 71, pp. 1497-1505 (1997).
Khromykh (Current Opinion in Molecular Therapeutics) 2(5), pp. 555-569 (2000).
Polo et al., Journal of Virology, vol. 71, pp. 5366-5374 (1997).
Fields et al., Virology—Third Edition, pp. 931-937 (1996).
C. Beard et al., “Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine”, J. Biotechnol., vol. 73, pp. 243-249 (1999).
N. Bhamarapravati et al., “Live attenuated tetravalent dengue vaccine”, Vaccine—18 Suppl, vol. 2, pp. 44-47 (2000).
M.A. Brinton et al., “Immune mediated and inherited defenses against flaviviruses”, Clin. Diagn. Virol., vol. 10, pp. 129-139 (1998).
M.J. Cardosa et al, “Dengue vaccine design: issues and challenges”, Br. Med. Bull., 54(2), pp. 395-405 (1998).
T.J. Chambers et al, “Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting”, Vaccine, 15(14), pp. 1494-1502 (1997).
T.J. Chambers et al, “Flavivirus Genome Organization, Expression and Replication”, Ann Rev Microbiol, vol. 44, pp. 649-688 (1990).
B. Falgout et al., “Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NSI protects against lethal Dengue virus encephalitis”, J. Virol., vol. 64, pp. 4356-4363 (1990).
S.B. Halstead et al., “Pathogenesis of Dengue: Challenges to Molecular Biology”, Science, vol. 239, pp. 476-481 (1988).
F.X. Heinz et al., “Epitope Mapping of Flavivirus Glycoproteins”, Adv. Virus Res., vol. 31, pp. 103-168 (1986).
E.A. Henchal et al., “Synergistic Interactions of Anti-NS1 Monoclonal Antibodies Protect Passively Immunized Mice From Lethal Challenge with Dengue 2 Virus”, J. Gen. Virol., vol. 69, pp. 2101-2107 (1988).
K. Irie et al., “Dengue virus type 2 compelte genome”, NCB1 Database Accession No. M29095 (1993).
N. Kanesa-Thasan et al., “Safety and Immunogenicity of Attenuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers”, Vaccine, vol. 19, pp. 3179-3188 (2001).
X. Pang et al., “Development of Dengue Virus Replicons Expressing HIV-1 gp120 and Other Heterologous Genes: A Potential Future Tool for Dual Vaccination Against Dengue Virus and HIV”, BMC Microbiology, 1(28), pp. 1-9 (2002).
X. Pang et al., “Development of Dengue Virus Type 2 Replicons Capable of Prolonged Expression in Host Cells”, BMC Microbiology, 1(18), pp. 1-7 (2002).
Dayton Andrew I.
Pang Xiaowu
Zhang Mingjie
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Mosher Mary E
The United States of America as represented by the Secretary, De
LandOfFree
Subgenomic replicons of the flavivirus dengue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Subgenomic replicons of the flavivirus dengue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subgenomic replicons of the flavivirus dengue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258052